These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22044312)

  • 1. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia.
    Costello RT; Knoblauch B; Sanchez C; Mercier D; Le Treut T; Sébahoun G
    Immunology; 2012 Feb; 135(2):151-7. PubMed ID: 22044312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy.
    Costello RT; Boehrer A; Sanchez C; Mercier D; Baier C; Le Treut T; Sébahoun G
    Immunology; 2013 Jul; 139(3):338-41. PubMed ID: 23360454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
    Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
    Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
    Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
    Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients.
    Mercier-Bataille D; Sanchez C; Baier C; Le Treut T; Mounier N; Mokhtari S; Olive D; Baumstarck K; Sébahoun G; Besson C; Costello RT
    AIDS Res Ther; 2014; 11():38. PubMed ID: 25908934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
    Veuillen C; Aurran-Schleinitz T; Castellano R; Rey J; Mallet F; Orlanducci F; Pouyet L; Just-Landi S; Coso D; Ivanov V; Carcopino X; Bouabdallah R; Collette Y; Fauriat C; Olive D
    J Clin Immunol; 2012 Jun; 32(3):632-46. PubMed ID: 22318393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.
    Parry HM; Stevens T; Oldreive C; Zadran B; McSkeane T; Rudzki Z; Paneesha S; Chadwick C; Stankovic T; Pratt G; Zuo J; Moss P
    Oncotarget; 2016 Oct; 7(42):68513-68526. PubMed ID: 27655680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.
    Hadadi L; Hafezi M; Amirzargar AA; Sharifian RA; Abediankenari S; Asgarian-Omran H
    Oncol Res Treat; 2019; 42(4):202-208. PubMed ID: 30870839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
    Reiners KS; Topolar D; Henke A; Simhadri VR; Kessler J; Sauer M; Bessler M; Hansen HP; Tawadros S; Herling M; Krönke M; Hallek M; Pogge von Strandmann E
    Blood; 2013 May; 121(18):3658-65. PubMed ID: 23509156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
    Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
    Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
    Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
    Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha.
    Katrinakis G; Kyriakou D; Papadaki H; Kalokyri I; Markidou F; Eliopoulos GD
    Acta Haematol; 1996; 96(1):16-23. PubMed ID: 8677756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
    Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
    Front Immunol; 2021; 12():619069. PubMed ID: 34108958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
    Sanchez CJ; Le Treut T; Boehrer A; Knoblauch B; Imbert J; Olive D; Costello RT
    Cancer Immunol Immunother; 2011 Jan; 60(1):1-13. PubMed ID: 20697893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
    Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.
    Palmer S; Hanson CA; Zent CS; Porrata LF; Laplant B; Geyer SM; Markovic SN; Call TG; Bowen DA; Jelinek DF; Kay NE; Shanafelt TD
    Br J Haematol; 2008 May; 141(5):607-14. PubMed ID: 18384436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.